Following engraftment of donor hematopoietic cells and induction of host-versus-graft tolerance, immunocompetent lymphocytes of donor origin can induce graftversus-leukemia (GVL) and graft-versus-tumor (GVT) effects. Engraftment of allogeneic bone marrow cells can be accomplished following non-myeloablative conditioning while possibly controlling graft-versus-host disease (GVHD). GVL and GVT effects may thus be successfully accomplished following non-myeloablative stem cell transplantation (NST) as shown by data derived from experimental animals and man. Bone Marrow Transplantation (2000) 25, Suppl. 25, S54-S57. Keywords: hematologic malignancies; bone marrow transplantation; nonmyeloablative stem cell transplantation; graft-versus-leukemia; graft-versus-host disease, chimeras Allogeneic bone marrow transplantation (BMT) represents the only modality for treatment of hematologic malignancies as well as for replacement of genetically abnormal stem cells with normal donor stem cells, thus presenting an ultimate treatment of choice for patients with many lifethreatening malignant and genetic disorders. Treatmentrelated toxicity and mortality, resulting in part from myeloablative chemoradiotherapy, still represent a barrier to successful BMT and are prohibitive in considering larger scale clinical application of stem cell transplantation for extending the indications for the treatment of larger number of patients in need, including a variety of genetic diseases that may be correctable by BMT exclusively. We recently introduced a new concept in an attempt to replace myeloablative conditioning with well-tolerated nonmyeloablative conditioning.
Allogeneic bone marrow transplantation (BMT) represents the only modality for treatment of hematologic malignancies as well as for replacement of genetically abnormal stem cells with normal donor stem cells, thus presenting an ultimate treatment of choice for patients with many lifethreatening malignant and genetic disorders. Treatmentrelated toxicity and mortality, resulting in part from myeloablative chemoradiotherapy, still represent a barrier to successful BMT and are prohibitive in considering larger scale clinical application of stem cell transplantation for extending the indications for the treatment of larger number of patients in need, including a variety of genetic diseases that may be correctable by BMT exclusively. We recently introduced a new concept in an attempt to replace myeloablative conditioning with well-tolerated nonmyeloablative conditioning. [1] [2] [3] [4] The first indication that stable engraftment of allogeneic stem cells can be accomplished (even across MHC barriers) without myeloablative conditioning was obtained in the early 1970s when we showed in pre-clinical animal models (mice, rats and dogs) that mixed chimerism and bilateral tolerance of host vs graft and graft vs host could be accomplished following conditioning with total lymphoid irradiation (TLI). [5] [6] [7] [8] [9] We have documented that mixed chimerism resulted following administration of low stem cell Correspondence: S Slavin, Dept of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah University Hospital, Jerusalem 91120, Israel numbers whereas chimeras could be converted to full donor type chimeras by tripling the number of donor stem cells. 7 Using the same animal model with a murine model of B cell leukemia/lymphoma (BCL1), we have subsequently demonstrated that GVL and GVT effects could be induced independently of GVHD following nonmyeloablative conditioning. 10, 11 In more recent clinical studies based on the preclinical data in mice, we have documented the efficacy of DLI for treatment and prevention of relapse in patients with leukemia. [12] [13] [14] The aforementioned experimental and clinical background provided the rationale for more recent studies involving intentional nonmyeloablative conditioning for induction of host vs graft tolerance, with donor stem cells serving for induction of host vs graft tolerance to set the stage for post-transplant DLI. Sustained engraftment with nonmyeloablative conditioning was first established by using a combination of Cytoxan and anti-T lymphocyte globulin (Fresenius AG, Berlin, Germany) (manuscript in preparation) and subsequently much more consistently with fludarabine-based regimens for induction of a window of immunosuppression for engraftment of stem cells.
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Complete response to donor lymphocyte infusion, despite previous resistance to all alternative anticancer modalities, 12, 13 led to the hypothesis that perhaps Mother Nature's tool, circulating alloreactive lymphocytes, may be much more effective in eradicating the 'last tumor cell' than are maximum tolerated doses of chemoradiotherapy. The consequences of this working hypothesis were self-evident. If myeloablative conditioning, no matter how strong, is unlikely to eradicate the last tumor cell, whereas alloreactive donor lymphocytes can do so, then the latter should be our first choice.
Our new protocol in preparation for allogeneic non-myeloablative stem cell transplantation (NST) is based on the following: (1) We have documented graft-versus-leukemia, graft-versus-lymphoma and graft-vs-genetically abnormal stem cell effect in patients with genetic diseases with recurrent disease following BMT, 12, 13, 15 suggesting that immunocompetent donor lymphocytes may eradicate residual host stem cells, including those resistant to myeloablative doses of chemoradiotherapy; (2) Complete replacement of malignant as well as normal hematopoietic cells of host origin can be accomplished by non-myeloablative conditioning, through GVL effects that may be mediated by donor T cells recognizing allogeneic host stem cells and their progeny, resulting in elimination of the host immunohematopoietic system, which is being replaced by donor stem cells facilitated by donor T cells. Elimination of all Cell therapy of cancer S Slavin et al S55 host-type hematopoietic cells by alloreactive donor T cells can be equally or even more effective than myeloablative conditioning, possibly with minimal procedure-related toxicity and mortality. 4 Based on the observations in experimental animals and the preliminary clinical studies, we have proposed the use of the same regimen for routine treatment of hematologic malignancies as well as non-malignant diseases, including genetic diseases, using a protocol which focuses on better immunosuppression and less myeloablation, using no radiation at all, aiming for stem cell engraftment for establishing host vs graft tolerance to enable durable engraftment of donor alloreactive T cells for elimination of residual hematopoietic stem cells of host origin. Overall, the new trend is designed towards clinical application of immunotherapy mediated by alloreactive lymphocytes rather than more aggressive chemoradiotherapy.
Methods
In experimental animals mixed chimerism was used to induce bilateral host vs graft and graft vs host transplantation tolerance using either the total lymphoid irradiation (TLI) method as previously described [5] [6] [7] or clonal deletion of alloreactive host anti-donor cells 16 as previously described in detail. Anti-tumor effects were induced by alloreactive donor lymphocytes present in the graft or whenever required, using late post-transplant donor lymphocyte infusion (DLI). 17 In clinical practice, we will review the outcome of the first 100 patients that underwent NST for all standard indications for BMT including acute and chronic leukemia, secondary leukemia, resistant non-Hodgkin's lymphoma (NHL), Hodgkin's disease (HD), myelodysplastic syndromes, multiple myeloma, and non-malignant diseases correctable by BMT. 4 Conditioning consisted of basic immunosuppression with fludarabine 30 mg/m 2 /day × 6 days (Schering AG, Berlin, Germany), followed by two daily oral doses of busulfan 4 mg/kg, or two daily doses of cytoxan 60 mg/kg, or a single low-dose total body irradiation (TBI) 200 cGy prior to infusion of donor stem cells. Rabbit anti-human T lymphocyte globulin 5-10 mg/kg (Fresenius AG, Munich, Germany) was given to recipients of busulfan followed by two collections of G-CSF (Neupogen; Amgen) mobilized peripheral blood stem cells (5 g twice daily for 5 days). Low-dose cyclosporin A (3 mg/kg) (CsA) was used as the only anti-GVHD prophylaxis, starting on day −1, given usually for less than 100 days. The patient with Fanconi's anemia and the patients with severe aplastic anemia were treated with cytoxan instead of busulfan (10 mg/g and 60 mg/kg on 2 consecutive days, respectively).
Results
We have previously documented that following conditioning of fully immunocompetent recipient rodents and outbred dogs with non-myeloablative conditioning mixed chimerism could be accomplished following infusion of Bone Marrow Transplantation unmodified bone marrow stem cells. [5] [6] [7] [8] [9] We have shown that chimeras prepared with TLI could resist BCL 1 and solid lymphosarcoma, 1 BCL 1 , 9 lymphosarcoma 10 and breast cancer. 11 More recently, we have shown that chimeras prepared with clonal deletion of host vs graft alloreactive cells 16 could successfully resist BCL1 independently of GVHD. All of the basic data in preclinical animal models suggested that effective GVL effects could result in cure of otherwise lethal leukemia by allogeneic cell therapy without using additional anti-cancer modalities. These observations, supported by the documented efficacy of DLI 12, 13 provided the scientific rational for non-myeloablative stem cell transplantation for the treatment of hematologic malignancies.
The fludarabine-based preparatory regimen, using busulfan, cytoxan or a single dose of TBI proved to be well tolerated, with some patients going through the whole transplant procedure with continuous oral caloric intake, with no support of blood products and no septic episodes. All patients with a matched sibling featured durable three-lineage engraftment complete replacement of host to donor hematopoietic cells, occasionally after a transient stage of mixed chimerism, following discontinuation of CsA. Day 100 mortality was 4% for standard risk cases (5% malignant diseases and 0% in patients with non-malignant diseases).
Allogeneic bone marrow or blood stem cell transplantation following conditioning with the NST protocol based on the use of busulfan was given to Ͼ100 patients with hematologic malignancies and also with non-malignant indication for BMT. Of the first cohort of patients, 70 were treated for hematologic malignancy using a compatible sibling, 16 patients received a graft from a matched unrelated donor (MUD) and nine patients received an allograft following failure of autologous bone marrow or blood stem cell transplantation. Patients were age range 3-63, median 38, with CML (n = 19); AML (n = 17); ALL (n = 10); NHL (n = 15); MDS and 2nd leukemia (n = 6); Hodgkin's disease (n = 2) and multiple myeloma (n = 1)). Patients received fully matched (n = 66) or single locus mismatched (n = 4) stem cells on day 0. The protocol was very well tolerated by patients of all age groups. Day 100 mortality was 4%; 0% in patients with non-malignant diseases and 7% in patients with malignancy. Fast and durable engraftment was observed in all patients with a matched sibling. Persistent evidence of disease or recurrent disease in mixed chimeras was treated by discontinuation of CsA or by graded increments of DLI with 10 of 15 responders. After 3 years, with an observation period of 3-39 months (median 24 months) actuarial probability of survival was 68% and disease-free survival was 48%. Corresponding numbers for MUD at 12 months were 75% and 70%, and at 18 months was 48%, respectively. Normal pregnancy has already been observed in one patient with acute leukemia treated similarly, who married 2 months after completion of NST and became pregnant 1 year later. Interestingly, however, acute and to a lesser extent chronic GVHD, still remain the single major problem, especially after discontinuation of CsA.
Discussion
Earlier experience in animal models and our cumulative experience in man, suggest that in principle, NST may be an attractive alternative approach for BMT candidates, particularly infants and children with malignant and nonmalignant indications for BMT, including genetic diseases with an indication for stem cell transplantation or replacement therapy. Non-myeloablative conditioning is associated with significantly less immediate and long-term procedurerelated toxicity and mortality. Using NST instead of myeloablative chemoradiotherapy, we observed, as anticipated, substantially less immediate side-effects, procedure-related toxicity and mortality. Longer observations are required to confirm decreased incidence of long-term complications, such as growth retardation, multiple endocrine dysfunction and sterility. Non-myeloablative conditioning in preparation for allogeneic stem cell transplantation may thus represent a novel treatment of choice for patients with lifethreatening malignant and non-malignant diseases in need of BMT. Larger cohorts of patients and longer observation periods will be required to assess whether NST will result in better event-free and disease-free survival as compared with conventional myeloablative BMT. Likewise, there is a need to confirm that NST may provide an option for the cure of elderly individuals in need of BMT, who were not considered eligible until recently due to anticipated unacceptable procedure-related toxicity and mortality. Similar observations were reported in other centers in experimental animals 19, 20 and in humans. 21, 22 Future wider clinical applications of nonmyeloablative conditioning may also be applicable for patients with genetic disorders and life-threatening autoimmune disorders as was already suggested in one patient with psoriatic arthritis treated with NST for CML, and successfully cured of both disorders (submitted for publication).
Using Winn-type co-transfer experiments, our group have clearly shown that intravenous injection of lethal doses of metastatic breast cancer cells together with syngeneic or semi-allogeneic lymphocytes failed to prevent tumor growth in mice, whereas similar inoculation of tumor cells together with allogeneic lymphocytes completely prevented tumor growth in all recipients. 23 Our data may thus suggest that allogeneic cell therapy may completely prevent hematogenous spread of metastases. However, it still remains to be seen whether the intensity of GVT required to eradicate well established metastases can be accomplished without severe GVHD. It also is not yet clear whether the targets of alloreactive lymphocytes and GVL-or GVTspecific lymphocytes are different, although indirect evidence suggests that, under specific circumstances, special T cell clones may be involved.
In conclusion, ongoing clinical studies suggest that NST could serve as the basis for sustained engraftment of donor stem cells for the treatment of malignant and non-malignant diseases for all standard indications of BMT for all age groups. Benign post-transplant course made it possible to offer NST with minimal procedure-related toxicity and mortality for elderly individuals, without upper age limit, as well as for high-risk patients who could not be considered as eligible candidates using standard conditioning regimens. The feasibility of safer BMT based on the use of NST may open new horizons for cellular therapy for malignant and non-malignant diseases, including autoimmune disorders and AIDS, and for induction of transplantation tolerance to cellular and perfused organ allografts.
